Chih-Ping Mao, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Annexin A5 | 1 | 2018 | 103 | 0.610 |
Why?
|
Vaccines, DNA | 5 | 2013 | 286 | 0.560 |
Why?
|
Histocompatibility Antigens | 1 | 2018 | 467 | 0.560 |
Why?
|
RNA Interference | 4 | 2010 | 2846 | 0.530 |
Why?
|
Cancer Vaccines | 6 | 2015 | 1046 | 0.350 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2018 | 2536 | 0.320 |
Why?
|
Proteins | 1 | 2021 | 6029 | 0.270 |
Why?
|
Viral Envelope Proteins | 1 | 2009 | 638 | 0.260 |
Why?
|
Dendritic Cells | 8 | 2019 | 2725 | 0.240 |
Why?
|
Tumor Escape | 3 | 2018 | 370 | 0.210 |
Why?
|
DNA, Viral | 1 | 2009 | 2194 | 0.210 |
Why?
|
Immunotherapy | 4 | 2018 | 4642 | 0.210 |
Why?
|
Antigens, Viral | 2 | 2020 | 980 | 0.200 |
Why?
|
Neoplastic Stem Cells | 3 | 2017 | 1347 | 0.200 |
Why?
|
T-Lymphocytes | 2 | 2018 | 10181 | 0.200 |
Why?
|
Mitochondrial ADP, ATP Translocases | 1 | 2018 | 11 | 0.160 |
Why?
|
Membrane Glycoproteins | 1 | 2009 | 3709 | 0.160 |
Why?
|
Mitochondrial Proton-Translocating ATPases | 1 | 2018 | 53 | 0.160 |
Why?
|
Neoplasms | 6 | 2019 | 22075 | 0.160 |
Why?
|
Toll-Like Receptor 9 | 1 | 2019 | 235 | 0.150 |
Why?
|
CD8-Positive T-Lymphocytes | 6 | 2015 | 4550 | 0.150 |
Why?
|
Immunoassay | 1 | 2020 | 746 | 0.140 |
Why?
|
Histone Deacetylase 1 | 1 | 2017 | 134 | 0.140 |
Why?
|
Drug Resistance, Multiple | 1 | 2017 | 254 | 0.130 |
Why?
|
Nanotechnology | 1 | 2021 | 709 | 0.130 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2018 | 620 | 0.120 |
Why?
|
Cross-Priming | 1 | 2015 | 75 | 0.120 |
Why?
|
Recombinant Fusion Proteins | 2 | 2013 | 3734 | 0.110 |
Why?
|
Tumor Microenvironment | 2 | 2019 | 3844 | 0.110 |
Why?
|
Immune Tolerance | 2 | 2013 | 2299 | 0.110 |
Why?
|
Homeodomain Proteins | 2 | 2012 | 2414 | 0.100 |
Why?
|
Papillomavirus E7 Proteins | 2 | 2009 | 111 | 0.100 |
Why?
|
Mice | 16 | 2019 | 81209 | 0.100 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 616 | 0.100 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2012 | 95 | 0.100 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 886 | 0.100 |
Why?
|
Antigen-Presenting Cells | 1 | 2015 | 967 | 0.090 |
Why?
|
Oncogene Proteins, Viral | 2 | 2009 | 341 | 0.090 |
Why?
|
Papillomavirus Vaccines | 2 | 2015 | 495 | 0.090 |
Why?
|
Mice, Inbred C57BL | 10 | 2018 | 22020 | 0.090 |
Why?
|
Immune System Phenomena | 1 | 2010 | 17 | 0.090 |
Why?
|
Neoplasms, Experimental | 2 | 2012 | 1229 | 0.090 |
Why?
|
RNA, Small Interfering | 2 | 2010 | 3442 | 0.090 |
Why?
|
Neoplasm Transplantation | 2 | 2012 | 2014 | 0.080 |
Why?
|
Antibodies, Viral | 1 | 2020 | 3142 | 0.080 |
Why?
|
Cell Fusion | 1 | 2009 | 293 | 0.080 |
Why?
|
Animals | 17 | 2019 | 167960 | 0.080 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2015 | 2448 | 0.080 |
Why?
|
Receptors, IgG | 1 | 2012 | 558 | 0.080 |
Why?
|
Fibula | 1 | 2011 | 265 | 0.080 |
Why?
|
Autoantigens | 1 | 2013 | 877 | 0.080 |
Why?
|
Transfection | 3 | 2013 | 5781 | 0.070 |
Why?
|
Fas Ligand Protein | 1 | 2008 | 215 | 0.070 |
Why?
|
Maxilla | 1 | 2011 | 491 | 0.070 |
Why?
|
Uterine Cervical Neoplasms | 2 | 2017 | 2003 | 0.070 |
Why?
|
Mice, Inbred NOD | 3 | 2018 | 1837 | 0.070 |
Why?
|
T-Lymphocytes, Cytotoxic | 4 | 2019 | 1765 | 0.070 |
Why?
|
Drug Administration Routes | 1 | 2007 | 150 | 0.070 |
Why?
|
Cell Death | 2 | 2009 | 1671 | 0.070 |
Why?
|
Epigenesis, Genetic | 2 | 2018 | 3759 | 0.070 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2009 | 778 | 0.070 |
Why?
|
Mice, SCID | 3 | 2018 | 2627 | 0.070 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2009 | 354 | 0.070 |
Why?
|
Cell Line, Tumor | 7 | 2019 | 16932 | 0.070 |
Why?
|
Lymphocyte Activation | 3 | 2019 | 5496 | 0.060 |
Why?
|
Mice, Transgenic | 1 | 2018 | 9530 | 0.060 |
Why?
|
Mitochondria | 1 | 2018 | 3601 | 0.060 |
Why?
|
Interleukin-2 | 1 | 2012 | 1889 | 0.060 |
Why?
|
Antineoplastic Agents | 3 | 2019 | 13627 | 0.060 |
Why?
|
Interferon-gamma | 2 | 2009 | 3157 | 0.060 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2015 | 3484 | 0.060 |
Why?
|
Disease Progression | 1 | 2020 | 13505 | 0.060 |
Why?
|
Vaccination | 2 | 2015 | 3359 | 0.050 |
Why?
|
Injections, Intramuscular | 2 | 2015 | 553 | 0.050 |
Why?
|
Surgical Flaps | 1 | 2011 | 1669 | 0.050 |
Why?
|
Gene Transfer Techniques | 1 | 2007 | 1204 | 0.050 |
Why?
|
Papillomaviridae | 1 | 2007 | 1117 | 0.050 |
Why?
|
Immunity, Cellular | 1 | 2007 | 1557 | 0.050 |
Why?
|
Combined Modality Therapy | 3 | 2018 | 8552 | 0.050 |
Why?
|
Colonic Neoplasms | 1 | 2012 | 2526 | 0.050 |
Why?
|
Intubation | 1 | 2020 | 139 | 0.040 |
Why?
|
Limit of Detection | 1 | 2020 | 280 | 0.040 |
Why?
|
Signal Transduction | 4 | 2019 | 23374 | 0.040 |
Why?
|
Female | 14 | 2020 | 391246 | 0.040 |
Why?
|
Antigens, Neoplasm | 2 | 2019 | 1998 | 0.040 |
Why?
|
Humans | 14 | 2021 | 760613 | 0.040 |
Why?
|
Cell Proliferation | 4 | 2017 | 10442 | 0.040 |
Why?
|
Protein Subunits | 1 | 2020 | 943 | 0.040 |
Why?
|
Cells, Cultured | 2 | 2009 | 18955 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 2018 | 480 | 0.030 |
Why?
|
Ovarian Neoplasms | 2 | 2012 | 4878 | 0.030 |
Why?
|
Immunoglobulin G | 2 | 2020 | 4542 | 0.030 |
Why?
|
Administration, Intravaginal | 1 | 2015 | 151 | 0.030 |
Why?
|
Apoptosis | 3 | 2017 | 9497 | 0.030 |
Why?
|
Muscle, Skeletal | 1 | 2009 | 4924 | 0.030 |
Why?
|
Acetylation | 1 | 2017 | 1062 | 0.030 |
Why?
|
Vaginal Neoplasms | 1 | 2015 | 104 | 0.030 |
Why?
|
Epitopes | 2 | 2013 | 2503 | 0.030 |
Why?
|
MicroRNAs | 1 | 2010 | 3787 | 0.030 |
Why?
|
Cisplatin | 1 | 2019 | 1643 | 0.030 |
Why?
|
Adjuvants, Pharmaceutic | 1 | 2013 | 49 | 0.030 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2018 | 5251 | 0.030 |
Why?
|
Intramolecular Oxidoreductases | 1 | 2013 | 105 | 0.030 |
Why?
|
Antibodies | 1 | 2020 | 2421 | 0.030 |
Why?
|
Genes, MHC Class I | 1 | 2013 | 240 | 0.030 |
Why?
|
beta 2-Microglobulin | 1 | 2013 | 328 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2020 | 2440 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 2017 | 1754 | 0.020 |
Why?
|
Permeability | 1 | 2013 | 719 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2006 | 8512 | 0.020 |
Why?
|
Antioxidants | 1 | 2018 | 1667 | 0.020 |
Why?
|
Luciferases | 1 | 2012 | 716 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2017 | 21029 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2017 | 6130 | 0.020 |
Why?
|
Toll-Like Receptor 4 | 1 | 2013 | 580 | 0.020 |
Why?
|
Cathelicidins | 1 | 2009 | 81 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2017 | 3583 | 0.020 |
Why?
|
Biolistics | 1 | 2008 | 15 | 0.020 |
Why?
|
Interferon Type I | 1 | 2013 | 559 | 0.020 |
Why?
|
Luciferases, Firefly | 1 | 2008 | 37 | 0.020 |
Why?
|
Electrophoretic Mobility Shift Assay | 1 | 2009 | 295 | 0.020 |
Why?
|
Prognosis | 2 | 2020 | 29661 | 0.020 |
Why?
|
Flow Cytometry | 2 | 2009 | 5869 | 0.020 |
Why?
|
Peritoneum | 1 | 2009 | 224 | 0.020 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2012 | 487 | 0.020 |
Why?
|
Injections, Intradermal | 1 | 2007 | 116 | 0.020 |
Why?
|
Antigen Presentation | 1 | 2013 | 1254 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2020 | 3736 | 0.020 |
Why?
|
Luminescent Measurements | 1 | 2009 | 378 | 0.020 |
Why?
|
Tumor Burden | 1 | 2013 | 1895 | 0.020 |
Why?
|
Histones | 1 | 2017 | 2582 | 0.020 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2009 | 899 | 0.020 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2009 | 717 | 0.020 |
Why?
|
Human papillomavirus 16 | 1 | 2008 | 265 | 0.020 |
Why?
|
Lectins, C-Type | 1 | 2009 | 587 | 0.020 |
Why?
|
Aged, 80 and over | 2 | 2020 | 58980 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2020 | 14661 | 0.020 |
Why?
|
Ligands | 1 | 2012 | 3276 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2012 | 2379 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2019 | 14374 | 0.010 |
Why?
|
Oxygen | 1 | 2015 | 4193 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2017 | 11152 | 0.010 |
Why?
|
Spleen | 1 | 2008 | 2298 | 0.010 |
Why?
|
Lymph Nodes | 1 | 2013 | 3486 | 0.010 |
Why?
|
Cell Movement | 1 | 2013 | 5206 | 0.010 |
Why?
|
Hospitalization | 1 | 2020 | 10789 | 0.010 |
Why?
|
Protein Binding | 1 | 2013 | 9335 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2012 | 2803 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8623 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18137 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2012 | 4496 | 0.010 |
Why?
|
Killer Cells, Natural | 1 | 2009 | 2203 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2012 | 7593 | 0.010 |
Why?
|
Antigens, CD | 1 | 2009 | 4000 | 0.010 |
Why?
|
Aged | 2 | 2020 | 169143 | 0.010 |
Why?
|
Drug Delivery Systems | 1 | 2009 | 2221 | 0.010 |
Why?
|
Cell Survival | 1 | 2007 | 5797 | 0.010 |
Why?
|
Repressor Proteins | 1 | 2007 | 2982 | 0.010 |
Why?
|
Middle Aged | 2 | 2020 | 220359 | 0.010 |
Why?
|
Survival Analysis | 1 | 2009 | 10185 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2008 | 4046 | 0.010 |
Why?
|
Macrophages | 1 | 2009 | 5745 | 0.010 |
Why?
|
Phenotype | 1 | 2012 | 16548 | 0.010 |
Why?
|
Male | 2 | 2020 | 359718 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2008 | 11902 | 0.010 |
Why?
|
Adult | 1 | 2020 | 220007 | 0.000 |
Why?
|